[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550781":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":40,"collaborators":44,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Ankara University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment arm","EXPERIMENTAL","Patients underwent Ga68 FAPI PET before immunotherapy",[13],"Diagnostic Test: Ga-68 FAPI PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Ga-68 FAPI PET\u002FCT","imaging of FAP expression of tumor before immunotherapy",[9],null,[22],{"facility":23,"status":24,"city":25,"state":20,"zip":26,"country":27,"countryCode":20,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Ankara University School of Medicine","RECRUITING","Ankara","06590","Turkey (Türkiye)",{"type":29,"coordinates":30},"Point",[31,32],32.85427,39.91987,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":20,"email":39},"Cigdem Soydal, Asc Prof","CONTACT","+903125957632","csoydal@ankara.edu.tr",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Cigdem Soydal","AsC Prof of Nuclear Medicine",[45,47,49],{"name":46,"class":6},"Liv Hospital Ankara",{"name":48,"class":6},"Social Sciences University of Ankara",{"name":50,"class":6},"Ankara Yildirim Beyazıt University","100550781","ga-68-fapi-pet-before-immunotherapy-100550781",false,"NCT06451536","Ga-68 FAPI PET Before Immunotherapy","Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma","FAPBI","Inclusion Criteria:\n\n* Having a histopathologically confirmed diagnosis of\n* Pleural Mesolthelioma\n* Patients scheduled for immunotherapy with anti-PDL-1 and\u002For anti-CTLA-4 antibodies as first or second line therapy\n* Patients who gave informed consent form to participate in the study\n\nExclusion Criteria:\n\n* ECOG\\>2\n* Patients who did not provide informed consent form to participate in the study","ALL","18 Years",{"count":62,"type":63},30,"ESTIMATED","INTERVENTIONAL",[66],"NA","It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET\u002FCT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.",[69],"Mesotheliomas Pleural","2024-06-04",{"date":72,"type":73},"2024-06-11","ACTUAL",{"date":75,"type":73},"2024-04-30",{"date":77,"type":63},"2025-04-30",{"name":5,"class":6},1]